相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号:
118414-82-7
- 规格:
1mLx10mM(inDMSO)/1mg/2mg/5mg/10mg/25mg/50mg/100mg
| 规格: | 1mLx10mM(inDMSO) | 产品价格: | ¥472.0 |
|---|---|---|---|
| 规格: | 1mg | 产品价格: | ¥214.0 |
| 规格: | 2mg | 产品价格: | ¥300.0 |
| 规格: | 5mg | 产品价格: | ¥462.0 |
| 规格: | 10mg | 产品价格: | ¥784.0 |
| 规格: | 25mg | 产品价格: | ¥1512.0 |
| 规格: | 50mg | 产品价格: | ¥2496.0 |
| 规格: | 100mg | 产品价格: | ¥3672.0 |
Product Introduction
Bioactivity
| 名称 | MK-886 |
| 描述 | MK-886 (L 663536) is an inhibitor of leukotriene biosynthesis, inhibiting 5-lipoxygenase-activating protein (FLAP). It is also a moderately potent PPARα antagonist. |
| 细胞实验 | IL-1β-stimulated A549 cells (5×106/ml) are pre-incubated with MK-886 (MK, 33 μM), indomethacin (Indo, 10 μM), celecoxib (Cele, 5 μM) or vehicle (DMSO) for 15 min prior to the addition of 30 μM arachidonic acid. After 15 min at 37 °C, the amount of released 6-keto PGF1α was assessed by ELISA as described in the Materials and methods section. (Only for Reference) |
| 激酶实验 | Enzyme assay is conducted in buffer containing 25 mM Tris, pH 8.0, 1 mM DTT, 1 mM spermine, 50 mM KCl, 0.01% Nonidet P-40, and 1 mM MgCl2. PARP reaction contains 0.1 μCi [3H]NAD+ (200 000 DPM), 1.5 μM NAD+, 150 nM biotinylated NAD+, 1 μg/mL activated calf thymus, and 1?5 nM PARP-1. Autoreactions utilizing SPA bead-based detection are carried out in 50 μL volumes in white 96-well plates. Compounds (e.g., MK-4827) are prepared in 11-point serial dilution in 96-well plate, 5 μL/well in 5% DMSO/Water (10× concentrated). Reactions are initiated by adding first 35 μL of PARP-1 enzyme in buffer and incubating for 5 min at room temperature and then 10 μL of NAD+ and DNA substrate mixture. After 3 h at room temperature, these reactions are terminated by the addition of 50 μL of streptavidin-SPA beads (2.5 mg/mL in 200 mM EDTA, pH 8). After 5 min, they are counted using a TopCount microplate scintillation counter. IC50 data is determined from inhibition curves at various substrate concentrations[1]. |
| 体外活性 | MK-886是一种抑制5-脂氧合酶激活蛋白(FLAP)的化合物,能强效抑制完整细胞内的白三烯生物合成,常用于确定5-脂氧合酶(EC 1.13.11.34)途径在细胞或动物模型中对炎症、过敏、癌症和心血管疾病的作用。MK-886对分离的COX-1的抑制作用(IC50=8 µM),可以阻断由COX-1衍生的产物12(S)-羟基-5-顺-8,10-反-十七碳三烯酸(12-HHT)和血栓素B2在人类洗涤血小板中对胶原蛋白以及外源性花生四烯酸的响应中的形成(IC50=13–15 µM)。分离的COX-2受到的影响较小(IC50=58 µM),在A549细胞中,MK-886(33 µM)未能抑制COX-2依赖的6-酮前列腺素(PG)F1α的形成。MK-886(10 µM)能抑制COX-1介导的血小板聚集反应,该反应由胶原蛋白或花生四烯酸诱导,而由凝血酶或U-46619(COX独立)诱导的聚集并不受影响[1]。 |
| 体内活性 | 连续每日通过腹腔注射MK-886会增加从前额叶皮层获取的大脑样本中GluR1的磷酸化水平。相比之下,单次注射MK-886并不改变大脑皮质GluR1的磷酸化水平[2]。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | 10% DMSO+90% Corn oil : 10 mg/mL (21.18 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : < 10 mg/mL (21.18 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Ethanol : 2.4 mg/mL (5.08 mM), Sonication is recommended. DMSO : 117.5 mg/mL (248.9 mM), Sonication is recommended. 10% DMSO+90% (20% SBE-β-CD in Saline) : < 10 mg/mL (21.18 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Saline : < 10 mg/mL (21.18 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. |
| 关键字 | PPARα | PPAR | Peroxisome proliferator-activated receptors | non-competitive | MK-886 | MK 886 | LeukotrieneReceptor | Leukotriene Receptor | leukotriene | L-663536 | L663536 | keratin-1 | Inhibitor | inhibit | FLAP | COX-2 | COX-1 | biosynthesis | Apoptosis | 5-LOX | 5-LO activating protein |
| 相关产品 | Trometamol | Formamide | Urea | Daidzein | Dimethyl phthalate | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Metronidazole | Sildenafil citrate | Stavudine | Tamoxifen |
| 相关库 | Inhibitor Library | Anti-Cancer Active Compound Library | Bioactive Compound Library | Bioactive Compounds Library Max | Anti-Diabetic Compound Library | Anti-Aging Compound Library | Nonsteroidal Anti-Inflammatory Compound Library | Nuclear Receptor Compound Library | GPCR Compound Library | Membrane Protein-targeted Compound Library | Immunology/Inflammation Compound Library | Pain-Related Compound Library |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验网络 第十九章 杂环化合物和生物碱 杂环化合物在自然界分布很广,其数量几乎占已知有机化合物的三分之一,用途也很多。许多重要的物质如叶绿素、血红素、核酸以及临床应用的一些有显著疗效的天然药物和合成药物等,都含有杂环化合物的结构。生物碱多是中草药的有效成分,绝大多数是含氮的杂环化合物。本章内容与医学关系密切,具有重要意义。
分子中具有高能键的化合物。在生物体内主要有上式(Ⅰ)和(Ⅱ)两种结构的高能化合物。其作用为贮藏能量(例如 ATP、肌酸磷酸)和作为产生 ATP源的中间代谢产物(例如磷酸烯醇丙酮酸)以及合成反应的中间物质(例如酰基辅酶 A),在蛋白质的结构( conformation)变化周期的第一阶段上(例如钠钾 ATP酶的羧基磷酸中间体)也具有重要作用。多数高等化合物具有磷酸基,但也有例外。
由不同种元素组成的纯净物叫做化合物。化合物一般有固定的组成。化合物的组成一般可用化学式表示。化合物具有确定的物理性质和化学性质,不同于其组成元素的性质。化合物中的元素不能用简单的机械方法或物理方法分开,而必须用化学方法才能分离。
技术资料暂无技术资料 索取技术资料









